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Background: Functional constipation is a common clinical complaint. Although the effectiveness of Ma Zi Ren Wan
for alleviating functional constipation symptoms has been proven in a previous randomized placebo-controlled
study, further evidence is needed to make clinical recommendations about Chinese herbal medicine. In particular, a
comparison with conventional western medicine for functional constipation patients is needed.
Methods/Design: This is a prospective, double-blinded, double dummy, randomized, controlled trial. After a 2-week
run-in period, eligible patients (Rome III) with excessive traditional Chinese medicine syndrome will randomly be
assigned to the Chinese medicine arm (Ma Zi Ren Wan and western medicine placebo), western medicine arm
(senna and Chinese medicine placebo) or placebo arm (Chinese medicine placebo and western medicine placebo).
Patients will undergo an 8-week treatment and an 8-week follow-up. The primary outcome is the responder rate for
complete spontaneous bowel movement (CSBM) during treatment. Patients with a mean increase of CSBM ≧1/week in
comparison with their baselines are defined as responders. The secondary outcomes include responder rate during
follow-up, changes of colonic transit as measured with radio-opaque markers, individual and global symptom
assessments, and reported adverse effects.
Discussion: This study is the first study to compare a Chinese Herbal Medicine (Ma Zi Ren Wan) with a laxative that is
commonly used in the clinical practice of western medicine, and with a placebo. This study will complete the
investigation of Ma Zi Ren Wan for functional constipation, and should, therefore, suggest recommendations for clinical
practice. Furthermore, the process of first conducting a systematic review, then implementing a dose determination
study followed by a placebo-control trial, and finally, comparing traditional Chinese medicine with an active conventional
medicine in a controlled trial can be a reference to other researches on Chinese medicine interventions in the future.
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Constipation affects a substantial portion of the popula-
tion, involving an estimated 12% to 19% of Americans [1],
14% of Asians [2], and up to 27% of the global population,
depending on demographic factors, sampling, and defin-
ition [3]. Treatments for constipation usually include fiber
supplements, osmotic and stimulant laxatives, stool soft-
eners, and sometimes enemas for refractory constipation
[4]. With the unsatisfactory response to current symptom-
atic treatments [5], many patients seek help from trad-
itional Chinese medicine (TCM), mostly by taking Chinese
herbal medicine (CHM) [4].
According to TCM theory, constipation can be divided
into excessive and deficient patterns based on the under-
lying etiology [6-8]. The former is characterized by the
presence of Heat or pathological accumulation of Qi (Qi
stagnation), while the latter is characterized by the defi-
ciency of Qi, Ying or Yang. The patent formula Ma Zi Ren
Wan (MZRW) was first recorded in the TCM classic,
‘Discussion of Cold-induced Disorders’ (ShangHanLun)
[6], and this formula has been commonly used for excessive
constipation in China and other Asian countries for more
than two thousand years since the Han Dynasty (A.D. 200).
It comprises six herbs: Semen Cannabis Sativae, Semen
Pruni Armeniacae, Radix Paeoniae, Fructus Immaturus
Citri Aurantii, Cortex Magnoliae and Radix et Rhizoma
Rhei. Through the combined action of these herbs, MZRW
can moisten the intestines, drain Heat, promote the
movement of Qi and unblock the bowel [9]. Based on
modern pharmaceutical studies, MZRW can stimulate
intestinal mucosa, increase secretion, accelerate intestinal
peristalsis and decrease water absorption [10,11].
Our research team began studying MZRW for functional
constipation (FC) in 2006. We found that available studies
had significant methodological flaws and lacked replicable
validation; thus, clinical findings could not be definitively
determined [12]. Therefore, the efficacy and safety of
MZRW had to be justified by first determining the optimal
dose. The currently recommended dose (5.0 g b.i.d.) was
compared with higher (7.5 g b.i.d.) and lower doses (2.5 g
b.i.d.); the study was supported by the WooFo Medical
Foundation. The dose of 7.5 g b.i.d. was found to have bet-
ter therapeutic effect than that of 2.5 and 5.0 g b.i.d. among
96 subjects (32 per arm). Second, MZRW in optimal dos-
age (7.5 g b.i.d.) was compared with a placebo for FC pa-
tients with excessive TCM Syndrome in a randomized,
double-blind clinical trial, which was supported by the
Health and Health Services Research Fund. In this study,
120 subjects were randomized into two arms (60 per arm).
Response rates for the MZRW and placebo groups were
43.3% and 8.3% during treatment, and 30.0% and 15.0% in
the follow-up period, respectively (P <0.05). Those in the
MZRW group showed benefits in terms of increased bowel
movement, relief in the severity of constipation andstraining, and effective reduction in the use of rescue ther-
apy when compared with placebo. These encouraging re-
sults suggested that the higher dose, which had not been
the recommended dosage in the Clinical Handbook of
Chinese Herbal Formulae [13], was in fact safe and effective
for alleviating FC when compared with the placebo [14].
In the current trial, we seek to evaluate the efficacy and
safety of MZRW by comparing it with the commonly used
stimulant laxative senna, as well as with a placebo, for pa-
tients with FC diagnosed with the TCM excessive syn-
drome. Senna is a stimulant laxative which facilitates the
passage of stools by altering intestinal electrolyte transport
and increasing intestinal motor activity [15]. Although no
placebo-controlled trials were found, laxatives containing
senna and fiber were more efficacious than lactulose [4].
Up to 26% of the patients underwent successful relief of
impaction with senna combined with mineral oil [16]. Due
to its low cost, safety and ease of ingestion, senna is widely
adopted and prescribed in clinical practice. The use of
senna remains the first-line treatment for the management
of constipation according to the local guidelines of in-
ternal medicine published by the Hospital Authority,
Hong Kong [17].
The study was financially supported by Food and Health
Bureau, Hong Kong, China, through its Health and Health
Services Research Fund (project no. 09101501) and was
registered with an identifier (NCT01695850) in Clinical
Trial.gov. This funding source had no role in the design of
this study and will not have any responsibility during its




This is a double-blinded, double-dummy, and placebo-
controlled trial with three parallel groups. The protocol
design was based on the recommendations made in the
‘Design of Treatment Trial for Functional Gastrointestinal
Disorders’, as proposed by the Rome III Working Team [3]
and the Consolidated Standards of Reporting Trials
(CONSORT) statement [18]. Two hundred and ninety-
one participants were recruited from Lee Kee Memorial
Dispensary (General outpatient clinic), Li Ka Shing
Specialist Clinic of Prince of Wales Hospital and clinics of
the School of Chinese Medicine, Hong Kong Baptist
University. After a 2-week run-in period, eligible subjects
were randomly assigned to one of three arms, the Chinese
medicine (CHM) arm, the western medicine (WM) arm,
and the placebo arm. The CHM arm received MZRW and
WM placebo, the WM arm received senna and the CHM
placebo, and the placebo arm received the CHM placebo
and the WM placebo. All three groups then underwent an
8-week treatment and an 8-week follow-up period. Five
visits in total were scheduled for each subject: one visit
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participant flowchart is listed in Figure 1 and the partici-
pant timeline is listed in Figure 2. The study protocol was
approved by the Hong Kong Baptist University Ethics
Committee on the Use of Human Subjects for Teaching
and Research (Approval no. HASC/10-11/16) and the Joint
Chinese University of Hong Kong-New Territories East
Cluster Clinical Research Ethics Committee (Approval no.
CRE-2013.192-T).
Participants
Setting: The study was performed at Lee Kee Memorial
Dispensary (general outpatient clinic), Li Ka ShingFigure 1 Participant flowchart.Specialist Clinic of Prince of Wales Hospital and Clinics of
the School of Chinese Medicine, and Hong Kong Baptist
University. The participants were enrolled from the public
through advertisements in local newspaper and out-
patient clinics.
Diagnostic criteria for FC (Rome III) [3]: 1) At least
two of the following occurrences more than 25% of the
time were required for a diagnosis of functional constipa-
tion: straining, lumpy or hard stools, sensation of incom-
plete evacuation, sensation of anorectal obstruction/
blockage, manual maneuvers to facilitate, or fewer than
three defecations per week; as well as 2) the rare presence
of loose stools without the use of laxatives; and also 3)
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Figure 2 Schedule of enrolment, intervention and assessments.
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syndrome.
Diagnostic criteria for excessive constipation in TCM
theory [6]: Any three of the chief symptom manifestations
of Heat and/or Qi stagnation were required for a diagnosis
of functional constipation: 1) dry, hard stools; 2) difficult
bowel movements; 3) abdominal distension, with or with-
out tenderness; 4) belching; 5) dry mouth or halitosis; 6)
red tongue with dry and/or yellow coating; and 7) Wiry
pulse.
Inclusion Criteria: Patients were included if they had all
of the following: 1) met the diagnostic criteria for FC
(Rome III); 2) met the diagnostic criteria for excessive con-
stipation in TCM theory; 3) were age 18 to 65 years (inclu-
sive); 4) had a complete spontaneous bowel movement
(CSBM) ≦2 times/week (CSBM is defined by feeling of
complete passage of stool after defecation, rather than par-
tial or incomplete evacuation, without the use of any laxa-
tive or enema within 24 hours) [19]; 5) exhibited severity
of constipation ≧3 points (on a 7-point scale) [20]; 6) had
a total symptom score ≧8 points (on a 7-point scale for
constipation-related symptoms); 7) had a normal colonic
examination (barium enema or colonoscopy) within five
years; and 8) had a normal liver and renal function in
blood test within 3 months.
Exclusion criteria: Patients were excluded if they had
one or more of the following: 1) drug-induced constipa-
tion; 2) secondary causes of constipation (that is, medicalhistory of diabetes mellitus, unstable thyroid disease); 3)
abdominal surgery within one year (that is, Caesarean op-
eration); 4) severe diseases (that is, cancer, acute asthma);
5) allergy to CHM (that is, G6PD deficiency); 6) pregnancy
or breast-feeding; or 7) psychiatric or addictive disorders
requiring medications with side effects of constipation.
Interventions
CHM intervention: As reported previously, MZRW is
composed of Fructus Cannabis (HuoMaRen), Radix et
Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao),
Semen Armeniacae Amarum (KuXingRen), Fructus
Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Offici-
nalis (HouPo) [10]. The composition and action of each
herb are summarized in Table 1 [17]. The placebo was
made from dextrin (76.03%), tea essence (23.61%), garden-
iaflavin (0.02%) and caramel (0.34%) to achieve color,
smell, taste and texture comparable to MZRW granules.
Patients were instructed to dissolve a sachet of granules
(7.5 g) in 150 ml of hot water; and to take the solution
orally twice daily for 8 weeks. Quality control of the crude
herbs authentication report is listed in Additional file 1.
WM intervention: An over-the-counter drug, Senokot,
was selected as the active control. Each tablet comprised
7.5 mg of Sennodide B [21]. Tablets were manufactured by
Reckitt Benckiser Company as circular, biconvex, greenish
brown tablets. The placebo was made of starch and color
to achieve an appearance comparable to Senokot. Patients
Table 1 Composition and action of Ma Zi Ren Wan (MZRW)
Ingredients % g/sachet g/day Action
Fructus Cannabis 35.7 10.8a 21.7 TCM: Moistening the bowel and relieving constipation
Pharmaceutical study: 1. Purgative effect, 2. Hypotensive effect
Radix et Rhizoma Rhei 17.9 5.4 10.9 TCM: Draining heat and relieving constipation
Pharmaceutical study: 1. Purgative effect, 2. Antimicrobial effect, 3. Antineoplastic
and ant mutagenic effect, 4. Hemostatic effect, 5. Immunosuppressive effect, 6. Choleretic effect
Semen Armeniacae Amarum 17.9 5.4 10.9 TCM: Reliving constipation by guiding Qi downward
Pharmaceutical study: 1. Laxative effect, 2. Antitussive and antiasthmatic effect,
3. Analgesic effect, 4. Antineoplastic and antimutagenic effect
Radix Paeoniae Albo 8.9 2.7 5.4 TCM: Nourishing Yin and retaining homeostasis
Pharmaceutical study: 1. Analgesic effect, 2. Antimicrobial and
anti-inflammatory effect, 3. Immunologic effect
Cortex Magnoliae Officinalis 10.7 3.3 6.5 TCM: Promoting circulation of Qi and relieving flatulence
Pharmaceutical study: 1. Central muscle-relaxation effect,
2. Anti-emetic effect, 3. Anti-ulcerative effect
4. Central inhibitory effect, 5. Antimicrobial effect
Fructus Aurantll Immaturus 8.9 2.7 5.4 TCM: Promoting circulation of Qi and relieving flatulence
Pharmaceutical study: 1. Diuretic effect, 2. Two-way effect on
gastrointestinal smooth muscle, 3. Cardiovascular stimulating effect
TCM, traditional Chinese medicine.
aEach gram of MZRW granule is equivalent to 4.05 g of raw herbs.
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The Senokot placebo tablet was made by Guangzhou Hua
hai Pharmaceuticals Co., Ltd,China according to the stan-
dards of Good Manufactory Practice (GMP).
Rescue medication/enema: Dulcolax tablets and Dulco-
lax suppositories [22] were provided to ensure bowel
movements only in those patients without bowel move-
ments for at least three consecutive days during the study.
The rescue medication was manufactured by Boehringer
Ingelheim Pharmaceuticals, Inc.,U.S.A.
MZRW granules and placebos were prepared by
PuraPharm (Nanning) Pharmaceuticals Col, Ltd.,China.
(lot nos. A1201839 for MZRW, and A1202071 for
placebos, respectively). The entire manufacturing process,
from authenticating the raw materials to the final product,
was in strict compliance with the standards of Good
Manufactory Practice (GMP) and Chinese Pharmacopoeia
2010 [23]. Acute toxicity testing of MZRW granules was
performed on mice, in order to monitor for toxicity of the
formula. The results showed that the maximum tolerance
dosage was 75 g/kg, equal to 300 times the dose tested
(Table 2). Chemical composition of the final products
were analyzed for contamination with heavy metals, toxic
elements, microbes and pesticide residue. Both MZRW
and CHM placebo granules were packed in sealed opaque
aluminium sachets and put in zip lock bags (28 sachets
each) while Senokot and WM placebo were put in plastic
bottles (56 tablets each). Only the treatment code was
printed outside the package to ensure successful blinding
of patients.Outcomes
Participants recorded stool frequency, stool form (on the 7-
point Bristol stool scale, ranging from ‘Separate hard lumps’
to ‘Watery’), and feeling of complete evacuation (yes/no).
They were also required to log intake of research medica-
tion, rescue drug and/or any other medication use through-
out the study in a daily diary. Principal investigators (PIs)
and research assistants (RAs) interviewed patients at the
end of Week 2 (baseline), Week 4 (within treatment), Week
8 (end of treatment), and Week 16 (end of follow-up), for
symptoms, compliance, and occurrence of adverse events.
Data on global symptom improvement, individual bowel
symptoms and stool consistency were collected.
Individual assessment of constipation and related
symptoms (severity of constipation, sensation of strain-
ing, incomplete evacuation, bloating, abdominal pain/
cramping, nausea and passing of gas) were recorded
using a 7-point ordinal scale (0 = not at all, 6 = very se-
vere) [see Additional file 2: Table S1] on a designated
form that participants filled out during every visit [3].
Global symptom improvement was defined as the parti-
cipant's subjective feeling of adequate relief of symp-
toms. For this purpose, participants were asked to rate
their impression of changes in constipation by scoring
(in comparison with their baseline (Week 2) scores)
their impression of these changes from 0 to 6 to repre-
sent that they were feeling markedly worse or better at
the respective extremes [3]. The response categories are
collapsed to simply ‘Improved’ for score 4 to 6, ‘Same’
for score 3 or ‘Worse’ for score 0 to 2 [24].
Table 2 Acute-toxicity of Ma Zi Ren Wan (MZRW)
Dosage g/kg
75 37.5 19.25 9.625 4.8125
Before administered drug 22.2 ± 1.1 20.4 ± 0.6 21.1 ± 1.6 21.8 ± 1.7 23.3 ± 1.9
After administered drug 28.7 ± 4.1 25.5 ± 3.0 25.5 ± 1.1 26.1 ± 1.1 30.3 ± 1.6
Sixty ICR mice, which were divided into five groups, were used in the acute-toxic test. The mice weighed 18 to 22 g. The drug was dissolved with distilled water
and administered 20 ml/kg orally. The details about dosage were as follows: 75 g/kg, 37.5 g/kg, 19.25 g/kg, 9.625 g/kg, and 4.8125 g/kg. The dosages equaled
300, 150, 75, 37.5, and 19.75 times of clinical dosage. Untoward reaction did not be observed after mice were administered the drug. Administered drug 7 days
later, no one died. The weight of mice was listed as Table 2.
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CSBM during the treatment period: a clinically mean-
ingful endpoint that combines an objective measure
(number of bowel movement) with a subjective measure
(feelings of patients as to completeness of defecation)
[25,26]. Participants with a mean increase of CSBM ≧1/
week compared with the last 14 days of the run-in
period are defined as responders.
Secondary outcomes will include the response rate for
CSBM during the follow-up period, including stool fre-
quency, changes from baseline in scores of individual
symptom assessment (severity of constipation, sensation
of straining, incomplete evacuation, bloating, cramping/
abdominal pain, nausea and passing of gas), and global
symptom assessment (improved, same or worse). Safety
profiles of MZRW will be assessed by determining im-
portant adverse events reported in participants’ diaries,
in follow-up interviews and in clinical laboratory evalu-
ations (for example, liver and renal function testing).
During the last visit, the success of blinding would be
evaluated for both investigators and patients, as to
whether CHM, WM or placebo had been taken. In par-
ticular, patients are asked to rate the appearance, color,
texture, taste and efficacy of the medication to try to de-
termine whether these factors were important in their
conclusion.
In addition, an objective estimate of changes in colonic
transit time is made based on a commercially available
radio-opaque Sitzmarks capsule (Konsyl Pharmaceuticals,
INC.,Easton, MD 21601,U.S.A).
Each gelatin capsule contains 24 barium sulfate em-
bedded polyvinyl chloride markers measuring 1 mm ×
4.5 mm. Plain radiographs of the abdomen are obtained
after patients swallow a capsule, for five days (120 hours)
before and 8 weeks after the treatment period. Normal
colonic transit is defined as expulsion of at least 80%
(19 or more) markers [27,28]. For patients with six or
more makers scattered throughout the colon, hypomo-
tility or colonic inertia is suggested. If six or more
markers are gathered in the rectosigmoid region with a
near normal transit of markers through the rest of the
colon, functional obstructive or dys-synergic defecation
is suspected [4,29].Recruitment procedures
Three strategies are used to recruit participants with FC.
The first relies on the participant bank of over 600 patients,
built up from prior research team work in functional con-
stipation related studies since 2007. The second relies on
referrals from the two study sites (Lee Kee Memorial
Dispensary and Li Ka Shing Specialist Clinic of Prince of
Wales Hospital) from our co-investigators (Co-Is). The third
strategy consists of posted advertisement in local newspapers
and a press conference to introduce our research.
All patients diagnosed with functional constipation by
the physicians (Co-Is) are referred to the principal investi-
gator (PI) and/or to the research assistants (RA) to deter-
mine whether they meet diagnostic criteria of excessive
constipation according to TCM theory. There is inconsist-
ency among different TCM practitioners regarding pattern
differentiation for FC. If any inconsistency occurs for an
individual patient concerning pattern identification, the
other senior CMP with more than 20 years clinical prac-
tice will be invited to make the diagnosis of TCM pattern
independently to ensure the consistence of the diagnosis.
The aims, procedures and nature of the study, and pos-
sible side effects are explained by the PI and/or the RAs
before a written consent form is obtained from each sub-
ject who agrees to participate. Moreover, patients are in-
formed that they are free to withdraw at any time during
the study. All patients undergo a 2-week, drug-free obser-
vation period. Meanwhile, they have to complete a stool
and symptom diary to confirm their diagnosis. Blood tests
of liver and renal function (blood urea, creatinine, alanine
transaminase and aspartate transaminase, alkaline phos-
phatase and bilirubin), and plain abdominal X-ray for co-
lonic transit study are arranged. Patients are considered
eligible for the study if their diaries reflect conformance
with the Rome III criteria for a diagnosis of functional
constipation, and if they also have normal liver and renal
function. Recruited patients will obtain their intervention
assignment from the PI and/or RAs.
Assignment and blinding
Block randomization was carried out in 1:1:1 ratio accord-
ing to the sequence generated with Random Allocation
Software (Version 1.0.0), Isfahan, Iran. The RA assigns
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sealed envelopes with consecutive randomization num-
bers. Treatment assignments will not be revealed and are
blinded to the patients and investigators (including statis-
ticians) until the entire study is completed. At the last
visit, all patients and the PI/RAs will complete a question-
naire about which treatment (CHM group, WM group or
placebo group) the patients received to evaluate the suc-
cess of blinding. Code breaks should only occur in excep-
tional circumstances when knowledge of the actual
treatment is absolutely essential for further management
of the patient.
Sample size calculation
From the results of the placebo-control study, the re-
sponse rate of MZRW was 43.3% [14]. Assuming the re-
sponse rates for TCM, senna and placebo were 40%,
20% and 10%, respectively. Therefore, 82 patients per
treatment group were deemed sufficient to achieve 80%
power in detecting treatment differences, based on two-
sided Chi-square test without continuity correction at a
significance level of 0.025 (used to maintain the overall
significance level at 5%). Further, assuming a 15% drop-
out rate, we concluded that a total of 291 patients (97
per arm) would need to be recruited to ensure statisti-
cally significant results. The calculation is performed
using StudySize 2.0 software, London, UK.Statistical analysis
All efficacy and safety analyses will be conducted accord-
ing to the intention-to-treat (ITT) principle. Missing
values will be imputed by the last-observation-carried-
forward method. The statistical analysis will be per-
formed using the Statistical Packages of Social Sciences
(SPSS) for Windows version 16.0. The statistical signifi-
cance is defined as two-sided P value of <0.05. Baseline
characteristics will be reported as mean (SD). Baseline
differences among the groups will be assessed with the
use of Student’s t-test for normally distributed continu-
ous variables and the non-parametric Mann-Whitney U
test for non-normally distributed variables. For categor-
ical variables, chi-squared test or Fisher’s exact test will
be used. Comparisons between groups will be conducted
by using an analysis of covariance (ANCOVA) with base-
line as covariate. All items and subscales will be com-
pared between groups for each 6-week treatment using
ANCOVA, with treatment group as a factor in the
model and baseline as the covariate. The changes from
baseline to endpoint of treatment in scores will be tested
with repeated measure analysis of variance (ANOVA).
Within group differences will be assessed with paired t-
test for normally distributed data and Wilcoxon signed-
rank test for non-normally distributed data.Data collection and handling of withdraw and dropout
This is an 18 week clinical trial, in which subjects need to
take research medication for 8 weeks, attend 5 assessment
visits, obtain 2 sets of blood tests and plain abdominal X-
rays, fill in a few sets of questionnaires, complete a patient
diary for the entire study period, and stop taking other
herbal medication and laxatives. Original data of study
forms will be entered and kept on file at the participating
site. All the files are to be stored in numerical order and
stored in a secure and accessible place. Participant files
will be maintained in storage for a period of 5 years.
In order to maximize subjects’ compliance, we first run a
thorough consent process for all participants by explaining
the details of the study schedule, potential side effects of
treatment, and the responsibilities that need to be under-
taken by subjects. Second, support and reassurance is pro-
vided during the whole study. Third, we will carefully
scrutinize subjects (during the 2-week run-in period) to ex-
clude ineligible and potentially low compliance individuals
before randomization. Fourth, a direct telephone hotline
and email account were established in order to optimize
active communication with patients and to respond to en-
quiries. Furthermore, additional visits can be arranged for
patients to see WM doctors or TCM practitioners if pa-
tients develop adverse events before the next scheduled
visit. If any patient expressed thoughts of withdrawing or
dropping out, we would try to help that individual deter-
mine the reason, and attempt to resolve any issues, in
order to keep the patient in the study.
In order to monitor the reported compliance of the
patients, the patients will be required to return the
remaining medications at treatment visits except the first
visit and last visit. Our research assistant will take a rec-
ord of each patient. 80% of the consumption will be con-
sidered good compliance. If the patients have no bowel
movement for at least three consecutive days during the
study rescue therapy as dulcolax suppository are pro-
vided to the patients.
The trial would be terminated in a specific subject
if he/she has: 1) presence of severe adverse effect; 2)
hypersensitivity towards research medication; 3) partici-
pation in another CHM research project; or 4) presence
of life-threatening disease. The whole research plan
would be terminated for the following circumstances: 1)
presence of serious adverse effect related to the research
medication with supportive evidence; or 2) completion
of all follow-up assessments.
Discussion
This randomized double-blind clinical trial is the third
clinical study our team has conducted on the effectiveness
of MZRW in FC patients with ‘excessive syndrome’ in
TCM diagnosis. The first study was the optimal dose de-
termination study comparing three different dose groups
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the optimal dose determined in the previous study com-
pared to the placebo [13]. To our knowledge, this study is
the first study to compare the Chinese herbal proprietary
medicine (MZRW) with commonly used laxative in the
clinical practice of Western medicine, as well as placebo.
This study will complete the investigation of MZRW, for
the common condition FC, and seeks to provide supportive
data to assist in informing clinical practice. Furthermore,
we feel that this sequential approach can be replicated for
determining clinical effectiveness of CHM interventions in
the future. That is, the sequence comprising first conduct-
ing a systematic review [12], then implementing a dose de-
termination study which is followed by a placebo-control
trial, and lastly comparing with an active control in blinded
clinical trial.
Another key process of the protocol is the use of com-
bined diagnostic criteria for both the western diagnosis of
Functional Constipation and the Chinese medicine diag-
nosis of excessive syndrome. In TCM, ‘syndromes’ are the
foundation for therapeutic principle. The identification of
TCM syndromes in clinical practice is subjective and is
highly dependent on personal experience, and thus that is
why randomized clinical trials of TCM are often lack of
syndrome diagnosis. However, by excluding TCM diagno-
ses, CHM studies must therefore also lose the most im-
portant characteristics of Chinese medicine treatment. In
this study, we conduct the trial according to the logistical
screening steps both in the specialist clinics of gastroenter-
ology and clinical centre of School of Chinese Medicine in
order to retain the optimal Chinese Medicine therapeutic
effect. The CM diagnostic criteria were arrived at by
consensus of all investigators prior to initiating the
trial, and are based on the standard criteria described
in Internal Chinese Medicine and Criteria of Diagnosis
and Therapeutic Effect of Disease and Syndromes in
Traditional Chinese Medicine.
Our systematic review of Chinese herbal medicine for
functional constipation, which compared CHM with pla-
cebo/no treatment, conventional western medicine (WM),
other CHM, and non-pharmaceutical interventions, also
indicated the need to seek strong evidence from well-
designed CHM clinical trials. The review analyzed 35 ran-
domized trials of CHM interventions and favored the
effectiveness of CHM in comparison with various controls
[12]. However, it is difficult to translate the results of such
studies due to the low methodological quality, different
compositions of the CHM formula and lack of standard
dosage preparations or manufacturing processes. Strengths
of this trial include our rigorous methodology and strict
quality control interventions. We described our method of
recruitment, sequence generation, allocation concealment
mechanism, and data collection methods in detail. In
addition, we reported the CHM intervention, MZRWaccording to Recommendations for Reporting Randomized
Controlled Trials of Herbal Interventions [30], including
dosage regimen and quantitative description, the indica-
tions of CM theory, the standardization of the products,
and so on.
The clinical trial protocol serves as the foundation, play-
ing a key role of study planning conduct reporting and ap-
praisal. To facilitate appropriate reference standards for
scientific, ethical and safety issues before the trial begins,
this protocol has been developed according to Consolidated
Standards of Reporting Trials (CONSORT) statement
[18], Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 [31] and SPIRIT 2013
explanation and elaboration: guidance for protocols of
clinical trials [32].
Conclusions
In conclusion, the results of this study are expected to
provide further consolidated evidence for the safety and
effectiveness of the CHM patent medication, MZRW, for
treatment of functional constipation in patients who also
meet diagnostic criteria for a TCM pattern of Excessive
syndrome.
Trial status
At the time of manuscript submission, the study has been
actively enrolling participants for one month. During this
enrollment period, a total of 20 subjects have been en-
rolled; no one has completed the treatment yet.
Additional files
Additional file 1: Crude herbs authentication report for the efficacy
and safety study of MZRW. The contents determination of Cortex
Magnoliae Officinalis and Radix et Rhizoma Rhei in MZRW were carried out
by using high-performance liquid chromatography (HPLC) and the results
are listed in Additional file 1.
Additional file 2: Table S1. Individual Assessment of Constipation and
Related Symptoms.
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